AstraZeneca - 31 Year Stock Split History | AZN

Stock split history for AstraZeneca since 1993. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
AstraZeneca Annual Stock Splits
AstraZeneca Quarterly Stock Splits
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $202.626B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $728.847B 75.49
Novo Nordisk (NVO) Denmark $381.440B 27.51
Johnson & Johnson (JNJ) United States $347.829B 14.11
AbbVie (ABBV) United States $310.275B 16.33
Merck (MRK) United States $248.031B 16.48
Novartis AG (NVS) Switzerland $198.493B 13.19
Pfizer (PFE) United States $149.382B 10.22
Sanofi (SNY) $121.080B 10.97
Bayer (BAYRY) Germany $19.295B 3.09
Innoviva (INVA) United States $1.117B 9.29